Thomas Catinazzo sold $3.2M of RLAY
Chief Financial Officer at Relay Therapeutics, Inc.. 187,163 shares at an average of $16.97, traded Jun 22, 2026, filed Jun 24, 2026.
Score components
- +22RoleCFO
- +25Trade size$3.2M at market
- +20Share of holdings soldSold 96% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-281061, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 22, 2026 | SOpen-market sale Common Stock10b5-1 | -17,717 | $17.01 | $301k | 177,461 | Jun 24, 2026 |
| Jun 22, 2026 | MOption exercise Common Stock10b5-1 | +56,323 | $5.04 | $284k | 233,784 | Jun 24, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stock10b5-1 | -56,323 | $16.97 | $956k | 177,461 | Jun 24, 2026 |
| Jun 22, 2026 | MOption exercise Common Stock10b5-1 | +61,563 | $5.22 | $321k | 239,024 | Jun 24, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stock10b5-1 | -61,563 | $16.97 | $1.0M | 177,461 | Jun 24, 2026 |
| Jun 22, 2026 | MOption exercise Common Stock10b5-1 | +51,560 | $4.45 | $229k | 229,021 | Jun 24, 2026 |
| Jun 22, 2026 | SOpen-market sale Common Stock10b5-1 | -51,560 | $16.97 | $875k | 177,461 | Jun 24, 2026 |
| Jun 22, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -56,323 | $0.00 | $0 | 0 | Jun 24, 2026 |
| Jun 22, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -61,563 | $0.00 | $0 | 0 | Jun 24, 2026 |
| Jun 22, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -51,560 | $0.00 | $0 | 223,440 | Jun 24, 2026 |
Related signals
Other insiders at Relay Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 15, 2026 | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $329k 17,717 shares | -14% | |
| Pro nowfree Oct 15, 2026 | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $872k 48,199 shares | -9% | |
| 26Weak | Relay Therapeutics, Inc. | Donald A Bergstrom President, R&D | $162k 8,530 shares | -2% | |
| 37Weak | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $336k 17,717 shares | -13% | |
| 44Moderate | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $913k 48,199 shares | -8% | |
| 19Weak | Relay Therapeutics, Inc. | Peter Rahmer See remarks | $90k 4,508 shares | -2% | |
| 57Moderate | Relay Therapeutics, Inc. | SVF Pauling (Cayman) Ltd owner | $116M 6,000,000 shares | -22% | |
| 37Weak | Relay Therapeutics, Inc. | Thomas Catinazzo Chief Financial Officer | $350k 17,717 shares | -11% | |
| 45Moderate | Relay Therapeutics, Inc. | Sanjiv Patel President and CEO | $980k 48,199 shares | -8% | |
| 41Moderate | Relay Therapeutics, Inc. | Donald A Bergstrom President, R&D | $42k 2,237 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.